The use of a C5aR1 inhibitor in combination with paclitaxel promotes interferon-γ (IFN-γ)-positive macrophage reprogramming increases the number and cytotoxicity of CXCR3+ effector and memory-CD8+T cells in the tumor microenvironment and enhances the efficacy and sensitivity of paclitaxel chemotherapy [114]. The gene discussed is CD8A; the disease is neoplasm.